US FDA staff says safety risks not clear for Vertex/CRISPR's gene therapy

Crispr Therapeutics AG

27/10/2023 14:10

Oct 27 (Reuters) - The U.S. Food and Drug
Administration's staff reviewers on Friday said safety risks of
Vertex Pharmaceuticals  VRTX.O  and CRISPR Therapeutics'
 CRSP.BN  sickle cell disease therapy were not clear. 
 
 

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini
Ganguli)
 ((Sriparna.Roy@thomsonreuters.com;))